AI-Implemented Biotech Inventions: An Office-Action Response Playbook

Why AI-Biotech Claims Trigger §101 / Art. 52(2)

The Alice/Mayo two-step framework treats any AI/ML claim as a candidate Step One abstract idea unless the claim recites an "inventive concept" that transforms the idea into a patent-eligible application. For pure-software claims the inventive concept usually lives in the technical improvement to the computer itself. For biotech claims, the inventive concept cannot live there — the AI contribution is non-structural — so the inventive concept has to live in the biological-feature contribution (a specific binding site, a specific therapeutic indication, a specific manufacturing step). When the claim fails to recite that biological-feature contribution with specificity, the examiner collapses the claim into "a computer-implemented method" and rejects on §101. The same shape plays out under EPO Art. 52(2) and the COMVIK approach: technical character has to be anchored in the overall claim scope, not in the algorithmic step.

The three biotech claim families that recur in this pattern are therapeutic-delivery claims (LNP + Cas9 mRNA + sgRNA + target cell), diagnostic claims (sequencing input + ML classifier + clinical decision output), and protein-engineering claims (sequence input + ML-guided mutation + candidate-protein output). Each family attempts to fold a non-structural AI step into a structurally specified biological system, and each family fails §101 in roughly the same place: the AI step is recited at a level of abstraction that the examiner can render as "doing it on a computer."

• Alice/Mayo Step One targets the ML contribution as a mental process when no biological feature is recited with specificity.
• EPO Art. 52(2) targets the ML contribution as a mathematical method unless technical character is anchored claim-wide.
• Therapeutic, diagnostic, and protein-engineering families all hit the same §101 trigger when the AI step is not bound to a concrete biological-feature contribution.

Claim-Atom Decomposition Across the Software–Biology Interface

Defensible amendment drafting starts with decomposition. Each AI-biotech claim is decomposed into three claim-atom groups: (i) the ML/AI contribution — model architecture, training corpus, inference step, output post-processing; (ii) the biological-feature contribution — sequence identity, structural element, binding affinity, delivery modality, therapeutic indication; (iii) the interface-spec — how the AI input maps to the biological output (feature extraction, embedding, scoring). Each atom is then scored against the cited references in the OA. The ML atoms rarely anticipate on their own; the biological-feature atoms often do; the interface-spec atoms determine whether the claim as a whole survives prior art.

The decomposition is what lets the amendment survive Alice/Mayo Step Two. When the interface-spec recitation is specific — "a trained convolutional neural network that maps myocardial strain-pattern features from a 12-lead ECG to a per-segment Nottingham risk classification" — the examiner has to either accept the recitation as inventive concept under §101 or attack the interface-spec recitation as unsupported under §112. Either fork produces a defensible position. Adding "implemented on a general-purpose computer" leaves the AI atom at its pre-decomposition level of abstraction and reopens Alice/Mayo Step One against the amended claim.

• ML/AI atom — model, training corpus, inference, post-processing
• Biological-feature atom — sequence, structure, affinity, modality, indication
• Interface-spec atom — concrete input/output mapping, not generic "implemented on a computer"

Amendment Drafting Under §112 + Art. 56

Amendment drafting under §112 written-description support has to walk two lines at once. The amended claim recitation has to bind the ML contribution to the biological-feature contribution with specificity sufficient to satisfy §112, but the binding has to be expressed in claim language that does not re-render the AI step as abstract on re-examination. The workable pattern is an interface-spec recitation drawn from the spec's example embodiments: a quantitative input mapping (vector-of-features → class), a specific structural output (sequence with explicit position numbering), or a tied outcome (binding-affinity ≤ X, yield ≥ Y, dosage ≤ Z). Each of these keeps the AI contribution within a structural-feather that the spec ties to the biological-feature contribution.

Under Art. 56 EPC, the amendment has to satisfy the COMVIK framework: technical character is anchored claim-wide, the ML step contributes to a technical effect within the claimed solution, and the effect is not purely cognitive. The defensible claim pattern adds a technical-effect recitation to the interface-spec — "the ML mapping is operative to reduce false-positive rate in the specific indication by ≥X% over a rule-based scoring baseline" — and ties that technical effect to a structural biological outcome (the diagnostic decision, the engineered sequence, the delivery efficiency). Without the technical-effect recitation the ML step remains in Art. 52(2) territory; with it, the claim crosses into Art. 56 inventive-step territory even where the cited reference loads the ML mapping itself.

Office-Action Response as a Loop, Not a Draft

An OA response on an AI-biotech claim is not a draft — it is a loop. The loop runs: OA parsing extracts the rejection grounds (Alice/Mayo Step One, §112 written-description, §102 anticipation, Art. 56 inventive-step, Art. 52(2) mathematical-method); claim-atom decomposition splits the claim into ML / biological-feature / interface-spec groups; amendment drafting produces candidate recitations anchored to spec paragraphs; re-search on Espacenet + Google Patents validates that the amended interface-spec recitation is not anticipated by a prior-art reference disclosing the same input/output mapping. The re-search step is what distinguishes an OA-Response-Agent from a draft-generation tool.

The loop's closure invariant: the amended claim must survive a second-pass corpus sweep at the new scope. Tools that stop at draft generation produce plausible language; tools that run the re-search loop produce plausible language that still anticipates under a fresh corpus query. For biotech counsel, the closed loop turns a four-day drafting cycle — manual §112 freshness check, manual Alice/Mayo Step One analysis, manual Art. 56 technical-effect argument — into a 90-minute loop where the only human review is the spec-anchor verification and the final interface-spec recitation.

The full before/after claim lattice for an AI-biotech OA is mapped in two worked examples in the companion AI-driven CRISPR novelty case study — including the blog-side companion on AI prior-art search and sequence-similarity novelty — with spec-anchor citations and §112 support flags per atom. The cross-link makes the working library: case studies for the full before/after lattice; learn pages for the statutory framing; blog notes for the working-practice view.

From Pilot to Production

Deploying AI-driven OA-response drafting on a real docket starts with one rejected AI-biotech claim. Pick an OA that cites an ML-augmented therapeutic, diagnostic, or protein-engineering claim, run the OA through the loop, and compare the agent output against your manual chain-of-thought on Alice/Mayo Step One, §112 written-description support, and Art. 56 technical-effect framing. The pilot is the calibration step — once decomposition maps to your claim-atom vocabulary and interface-spec recitation maps to your spec's example-embodiment inventory, the loop is ready for a production docket.

The two intake paths that work for biotech counsel are the free OA analysis at /audit and the Pilot Program at /pilot — both routes through the same ClaimForge chain and surface the same claim-atom decomposition, interface-spec recitation, and re-search validation. The companion Novelty-Essentials biotech guide walks through the structural-genus scoring model with worked examples for LNP-delivery, RNP-delivery, and ML-augmented diagnostic escape vectors. Together, the two blog notes, the AI-biotech case studies, and the Novelty-Essentials guide form a working library for prosecution counsel adopting AI on AI-implemented biotech claims.